PatientsVille.com LogoPatientsVille.com

Schizophrenia | Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine

Schizophrenia research study

What is the primary objective of this study?

The goal of this research is investigating the heart rate changes in schizophrenic and bipolar patients under the medication of aripiprazole and quetiapine. In the mean time, we are hoping further investigating the interrelationship of medicine dosage and heart rate change, in order to acquire the best relationship both effectiveness as well as safety in acceptable heart rate change of clinical suggestion.

Who is eligible to participate?

Inclusion Criteria: 1. Age between 20 to 50, all genders. 2. Psychiatry doctor diagnosed who met DSM-IV-TR criteria schizophrenia or bipolar patients and using antipsychotics. 3. Psychiatry doctor first diagnosed who met DSM-IV-TR criteria schizophrenia or bipolar patients and without using antipsychotics. 4. Participants understand the goal of this experiment and willing to cooperate for evaluating heart rate change measurement. Participants need to understand the procedure of this study. 5. Participants voluntarily join this interview, approximately 30-45min. 6. Clinical reviewed patient's condition need to use quetiapine or aripiprazole. Control group 1. Age between 20 to 50, all genders. 2. Psychiatry doctor diagnosed who exclude DSM-IV-TR schizophrenia or bipolar patients. 3. Participants understand the goal of this experiment and willing to cooperate for evaluating heart rate change measurement. Participants need to understand the procedure of this study. 4. Participants voluntarily join this interview, approximately 30-45min. Exclusion Criteria: Experimential Group: 1. Participants fail to understand the goal of this experiment and unwilling to cooperate for evaluating heart rate change measurement. 2. Participant has another major mental disease other than the inclusion criteria. 3. Participants have cardio-vascular disease, diabetes, hepatic cirrhosis, kidney disease, material abuser (smoking not excluded) and long-term-effective psychotics user. 4. Participant has combination diseases, it could seriously influence diagnosis. 5. Psychopathy or psychosis can not be categorized in defined group. 6. Clinical reviewed patient's condition need to switch other medicine. 7. Clinical reviewed patient's condition need to quite this experiment and record reasons. 8. Participants decide to quite experiment without any conditions. Control group 1. Participants fail to understand the goal of this experiment and unwilling to cooperate for evaluating heart rate change measurement. 2. Participants have cardio-vascular disease, diabetes, hepatic cirrhosis, kidney disease, material abuser (smoking not excluded) and long-term-effective psychotics user. 3. Participants decide to quite experiment without any conditions.

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Schizophrenia

Bipolar

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:Aripiprazole; QuetiapineAripiprazole Quetiapine

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

AripipazoleHeart rate change in schizophrenic and bipolar patients under the aripipazole and quetiapine medication

QuetiapineHeart rate change in schizophrenic and bipolar patients under the aripipazole and quetiapine medication

Study Status

Unknown status

Start Date: August 2009

Completed Date: June 2010

Phase: Phase 4

Type: Interventional

Design:

Primary Outcome:

Secondary Outcome:

Study sponsors, principal investigator, and references

Principal Investigator: Tsuo-Hung Lan, MD., PhD.

Lead Sponsor: Taichung Veterans General Hospital

Collaborator:

More information:https://clinicaltrials.gov/show/NCT01047215

Discuss Seroquel